Post-traumatic Stress Disorder Treatment Market Players:
- Jazz Pharmaceuticals plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bionomics Limited
- Merck KGaA
- Pfizer Inc.
- Aurobindo Pharma Limited
- GlaxoSmithKline plc (GSK plc)
- Viatris Inc.
- Jubilant Pharmova Ltd.
- H. Lundbeck A/S
- Camber Pharmaceuticals, Inc.
The PTSD treatment market is extremely fragmented, with both small enterprises and large companies in competition. To treat PTSD symptoms, pharmaceutical firms are developing and marketing both new and well-known drugs, like anxiolytics and antidepressants. The market is competitive and dynamic, with a constant focus on improving patient outcomes and innovation.
Some of the prominent players include:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of post-traumatic stress disorder treatment is assessed at USD 2.14 billion.
The global post-traumatic stress disorder treatment market size surpassed USD 2.04 billion in 2025 and is projected to grow at a CAGR of over 5.7%, reaching USD 3.55 billion revenue by 2035.
North America post-traumatic stress disorder (PTSD) treatment market will account for 40.70% share by 2035, attributed to high PTSD prevalence and demand for mental health care.
Key players in the market include Jazz Pharmaceuticals plc, Bionomics Limited, Merck KGaA, Pfizer Inc., Aurobindo Pharma Limited, GlaxoSmithKline plc (GSK plc), Viatris Inc., Jubilant Pharmova Ltd., H. Lundbeck A/S, Camber Pharmaceuticals, Inc..
